Pipeline | 2021 | 2022 | 2023 | 2024 | ||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1Q | 2Q | 3Q | 4Q | 1Q | 2Q | 3Q | 4Q | 1Q | 2Q | 3Q | 4Q | 1Q | 2Q | 3Q | 4Q | |
AZBT51105 T Cell Vaccine |
In vitro In vivo Pre-clinical |
|||||||||||||||
License out |
||||||||||||||||
AZBR52209 siRNA Delivery |
Target analysis In vitro In vivo Pre-clinical |
|||||||||||||||
License out |
||||||||||||||||
AZBE53206 ER Targeting |
Target analysis In vitro In vivo Pre-clinical |
|||||||||||||||
License out |
||||||||||||||||
AZBF11509 TYK2 Inhibitor |
Target analysis In vitro In vivo Pre-clinical |
|||||||||||||||
License out |
||||||||||||||||
AZBT12128 TRK Inhibitor |
Target analysis In vitro In vivo Pre-clinical |
|||||||||||||||
License out |
Faster discovery & development
Let you make quicker decisions
Customized discovery & optimization
Meet your specific needs and increase efficiency
In-house biochemistry laboratory for in-vitro
Provide you with more consistent and timely results
Vs
AZothBio’s in-house laboratories verify
in-silico results biologically and chemically.
Regardless of the success,
all test results go to ArchiSTA for strengthening the database.